For how we live.
Four separate trial emulations, each with a different comparator, all pointed the same direction. The strongest effect appeared among people being treated for alcohol use disorder.
A review lays out the evidence chain: animal studies showing reduced drug-seeking, one small human trial, and record-based analyses linking GLP-1 prescriptions to 40% fewer opioid overdoses.
No medication has proven effective for cocaine use disorder. A single psilocybin dose, paired with therapy, produced more abstinent days and a longer time to relapse than an active placebo.
The same drug sold as Zepbound and Mounjaro reduced cocaine-evoked dopamine release and blocked drug-associated place preference in rodents. It's animal data, not a human addiction treatment.
Six months out, 40.5% of smokers given one high dose of psilocybin plus therapy stayed abstinent, versus 10% on the nicotine patch plus the same therapy. The trial ran 82 people.
Compared with a diabetes drug from another class, GLP-1 agonists were followed by fewer new diagnoses of alcohol, opioid, nicotine and other substance use disorders.